The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Femen is a feminist activist group which uses topless protests as part of their campaigns against sex tourism religious institutions, sexism, and homophobia. Femen activists have been regularly detained by police in response to their protests. There is a long history of female breasts being used by comedians as a subject for comedy fodder (e.g., British comic Benny Hill's burlesque/slapstick routines).
=== Properties === The chemical properties of MDMA have been described. As a free base, MDMA is a colorless oil insoluble in water. The most common salt of MDMA is the hydrochloride salt. Pure MDMA hydrochloride is water-soluble and appears as a white or off-white powder or crystal.
It is noteworthy that several cell types become polyploid during organ development or in response to infections. For example, cardiomyocytes enhance their ploidy during terminal differentiation, while viral infections can induce cell fusion, and bacterial infections may lead to the formation of multinucleated giant cells in macrophages. Reflecting on the previous discussions, it is plausible to propose that PIDD1 might be activated in certain circumstances, which positions it as a promising candidate for pharmacological strategies aimed at influencing these processes.
Specific terms are used to describe nerves and their actions. A nerve that supplies information to the brain from an area of the body, or controls an action of the body is said to innervate that section of the body or organ. Other terms relate to whether the nerve affects the same side ("ipsilateral") or opposite side ("contralateral") of the body, to the part of the brain that supplies it.
Sources: en.wikipedia.org
The 1995 season was shortened by 18 games due to the players' strike that commenced the year before. Bagwell endured a slump through the month of May in which he batted .183. In June, his results started to improve as he batted .339 and followed up in July by driving in 31 runs. Both Bagwell and Derek Bell, included as a "Killer B," registered 31 RBI that month, breaking the monthly club RBI record. Bagwell had tied the previous record one year earlier to the month. He hit his first two career home runs against Maddux of the Atlanta Braves within a week, on May 28 and June 3. Maddux allowed only 8 home runs the entire season. On July 28 against the Colorado Rockies, Bagwell's 10th-inning home run tied the score and two innings later he scored the winning run for a 5–4 final score. For the third time in three seasons, an incoming pitch broke a bone in Bagwell's left hand: on this occasion, it was on July 30 from the Padres' Brian Williams. Rather than change his successful style, Bagwell resorted to wearing a heavily padded protective batting glove. He returned in September to bat .313 with five home runs and 21 RBI as Houston finished one game behind the Rockies for the NL wild card. Bagwell missed 30 games, appearing in 114 and batted .290 with 21 home runs. He won the 1995 ESPY Awards for Best Breakthrough Athlete and Outstanding Baseball Performer (later renamed "Best Major League Baseball Player"). After the season, he commenced a rigorous training program that enabled him to gain 20 pounds and increased his endurance for the long season.
Most navies prohibited women from serving on submarines, even after they had been permitted to serve on surface warships. The Royal Norwegian Navy became the first navy to allow women on its submarine crews in 1985. The Royal Danish Navy allowed female submariners in 1988. Others followed suit including the Swedish Navy (1989), the Royal Australian Navy (1998), the Spanish Navy (1999), the German Navy (2001) and the Canadian Navy (2002). In 1995, Solveig Krey of the Royal Norwegian Navy became the first female officer to assume command on a military submarine, HNoMS Kobben. On 8 December 2011, British Defence Secretary Philip Hammond announced that the UK's ban on women in submarines was to be lifted from 2013. Previously there were fears that women were more at risk from a build-up of carbon dioxide in the submarine. But a study showed no medical reason to exclude women, though pregnant women would still be excluded. Similar dangers to the pregnant woman and her fetus barred women from submarine service in Sweden in 1983, when all other positions were made available for them in the Swedish Navy. Today, pregnant women are still not allowed to serve on submarines in Sweden. However, the policymakers thought that it was discriminatory with a general ban and demanded that women should be tried on their individual merits and have their suitability evaluated and compared to other candidates. Further, they noted that a woman complying with such high demands is unlikely to become pregnant. In May 2014, three women became the RN's first female submariners.
== Properties == Protactinium is an actinide positioned in the periodic table to the left of uranium and to the right of thorium, and many of its physical properties are intermediate between its neighboring actinides. Protactinium is denser and more rigid than thorium, but is lighter than uranium; its melting point is lower than that of thorium, but higher than that of uranium. The thermal expansion, electrical, and thermal conductivities of these three elements are comparable and are typical of post-transition metals. The estimated shear modulus of protactinium is similar to that of titanium. Protactinium is a metal with silvery-gray luster that is preserved for some time in air. Protactinium easily reacts with oxygen, water vapor, and acids, but not with alkalis. At room temperature, protactinium crystallizes in the body-centered tetragonal structure, which can be regarded as distorted body-centered cubic lattice; this structure does not change upon compression up to 53 GPa. The structure changes to face-centered cubic (fcc) upon cooling from high temperature, at about 1200 °C. The thermal expansion coefficient of the tetragonal phase between room temperature and 700 °C is 9.9×10−6/°C. Protactinium is paramagnetic and no magnetic transitions are known for it at any temperature. It becomes superconductive at temperatures below 1.4 K. Protactinium tetrachloride is paramagnetic at room temperature, but becomes ferromagnetic when cooled to 182 K.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.